Back

Notification report

Full notification file


General information

Notification Number
B/ES/18/23

Member State to which the notification was sent
Spain

Date of acknowledgement from the Member State Competent Authority
20/09/2018

Title of the Project
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)

Proposed period of release:
01/11/2018 to 15/03/2025

Name of the Institute(s) or Company(ies)
Novartis Pharma AG, Postfach, 4002 Basel, Switzerland;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Austria; Belgium; Germany; Denmark; Spain; Finland; France; United Kingdom; Greece; Ireland; Italy; Luxembourg; Netherlands; Portugal; Sweden; Cyprus; Czech Republic; Estonia; Hungary; Lithuania; Latvia; Malta; Poland; Slovenia; Slovak Republic; Iceland; Liechtenstein; Norway; Bulgaria; Romania; Croatia;

Has the same GMO been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):
B/DE/15/PEI/2484; B/ES/15/08; B/ES/17/04; B/ES/18/16; B/ES/18/18; B/ES/18/19; B/NL/15/012;

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
Autologous T cells transduced with a replication-deficient HIV-1 derived viral vector to express a
chimeric (murine/human) antigen receptor (CAR).

Information relating to the recipient or parental organisms from wich the GMO is derived

Common Name	Genus	Species	Subspecies	Strain	Pathovar
Human	Homo	Sapiens	-	-	-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known